Selank + Semax 10mg + 10mg Review

The pairing of Selank and Semax in a single research vial reflects a deliberate attempt to combine two mechanistically distinct neuropeptides: one with documented anxiolytic and GABAergic properties, the other with established neurotrophin-upregulating and neuroprotective activity. Both peptides carry a substantial body of preclinical literature, a smaller but real body of early clinical data from Russian academic centers, and significant gaps in pharmacokinetic characterization and large-scale randomized controlled trial evidence. This review examines what the published, PubMed-indexed record actually says about each compound, what a combined-vial format does and does not provide evidence for, and how researchers sourcing this product should evaluate purity, reconstitution, and experimental design.

The article draws on peer-reviewed sources from Semiglazova, Uchakina, Zozulya, Bobyntsev, Gudasheva, and colleagues whose work forms the primary empirical base for these peptides, and it situates both compounds within the broader neuropeptide pharmacology literature.

Editor's Verdict

For researchers whose experimental questions span both the stress-anxiety axis and the neuroprotection-neurotrophin axis, this combined vial offers logistical convenience and reasonable per-milligram cost. The mechanistic complementarity is biologically plausible, but direct combination studies are absent from the indexed literature, which should be reflected in experimental design and interpretation.

Specifications

The combined vial contains both lyophilized peptides. Researchers should confirm with the vendor whether the two peptides are lyophilized together in a single cake or as separate lyophilates within the same vial, as this distinction affects reconstitution volume calculations and co-elution behavior on HPLC quality checks.

What It Is: Chemistry, Origin, and Sequence Detail

Selank: A Tuftsin Derivative Engineered for CNS Access

Selank is a linear heptapeptide bearing the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro, composed entirely of L-configured amino acids. ^[1] Its pharmacophore derives from tuftsin, the endogenous tetrapeptide Thr-Lys-Pro-Arg that is cleaved from the Fc region of the IgG heavy chain by tuftsinase and leucine aminopeptidase in the spleen and peripheral tissues. ^[2] Tuftsin itself is well characterized as an immunostimulatory signal, enhancing phagocyte activity and natural killer cell function, but its CNS bioavailability and psychotropic activity are limited by rapid enzymatic degradation and poor blood-brain barrier penetration. ^[2]

The molecular innovation in Selank was the C-terminal extension of the tuftsin core with a Pro-Gly-Pro tripeptide sequence, a motif borrowed from the connective-tissue remodeling literature where it appears in collagen degradation products and has demonstrated neuropeptide-like activity. ^[1] This extension serves two documented purposes: it substantially slows proteolytic cleavage of the parent tuftsin sequence by creating a sterically disfavored substrate for common dipeptidyl peptidases, and it introduces a propensity for beta-turn conformation in aqueous solution, which appears functionally important for CNS receptor interactions. ^[3] The acetate salt form, indexed on PubChem with the formula C35H61N11O11 plus acetate counterion, is the predominant commercial research form and carries an approximate molecular weight of 811.9 g/mol in the salt form, or approximately 751.9 g/mol as the free base. ^[2]

High-resolution structural data for Selank are sparse. No crystal structure of Selank bound to a GABA-A receptor or other named receptor target has been deposited in the Protein Data Bank as of publication. Mechanistic assignments therefore rest on functional binding studies, gene expression analyses, and behavioral pharmacology rather than direct structural biology, a limitation that researchers should account for when interpreting downstream signaling claims. ^[3]

Selank was developed at the V.V. Zakusov Research Institute of Pharmacology, Russian Academy of Medical Sciences, and has been granted official drug status in Russia for generalized anxiety disorder (GAD), neurasthenia, and stress-related cognitive disturbances under the brand name Selank (0.15% nasal solution). ^[1] This regulatory context is relevant to researchers because it means a portion of the available safety and efficacy data comes from regulatory submissions and open-label trials in Russian clinical settings, which carry their own methodological considerations regarding blinding, placebo controls, and outcome standardization.

Semax: ACTH Fragment With Neuroprotective Tail

Semax carries the sequence Met-Glu-His-Phe-Pro-Gly-Pro. Its first four residues, Met-Glu-His-Phe, correspond to the ACTH(4-7) fragment, which is the minimal pharmacologically active sequence of adrenocorticotropic hormone capable of influencing learning, memory, and stress behavior without stimulating adrenal steroidogenesis. ^[4] The ACTH(4-7) core was identified decades ago by De Wied and colleagues as the primary behavioral locus of ACTH's nootropic activity, and its synthetic analogs have been studied since the 1980s for cognitive enhancement potential.

The C-terminal Pro-Gly-Pro extension added to the ACTH core in Semax mirrors the structural strategy used for Selank: it improves metabolic stability, facilitates CNS delivery through the nasal mucosa, and appears to confer independent neurotrophic activity. ^[4] Semax is officially classified in Russia as a nootropic and neuroprotective drug, listed among "vital and essential medicines," and carries approved indications for ischemic stroke, chronic cerebrovascular insufficiency, and cognitive and stress-related conditions. ^[5]

The free-base molecular weight of Semax is approximately 858.0 g/mol, and its acetate salt is the typical research-grade form. The peptide is moderately hydrophilic, which supports reasonable water solubility for reconstitution but also means it does not partition efficiently into lipid-rich compartments, influencing its volume of distribution. ^[5]

Why These Two Peptides Are Co-Formulated

The commercial logic of combining Selank and Semax in a single vial is mechanistically plausible but not backed by specific combination studies. Selank primarily targets anxiety, stress resilience, and enkephalin degradation pathways, while Semax primarily targets neurotrophin upregulation, neuroprotection, and cognitive enhancement through BDNF and TrkB signaling. ^[6] The two pathways are not redundant, which theoretically reduces pharmacodynamic antagonism and creates the possibility of complementary action at a systems level. Researchers should treat this as an untested hypothesis rather than an established pharmacological claim and design combination experiments with appropriate single-arm controls for each peptide individually.

Mechanism of Action

GABA-A Receptor Modulation by Selank

Selank's most documented receptor-level action is allosteric potentiation of GABA-A receptors. Radioligand binding studies in rat cortical and cerebellar membrane preparations demonstrated that Selank increases the affinity of GABA for its binding site on GABA-A receptors without acting at the benzodiazepine binding site directly, a profile consistent with positive allosteric modulation rather than direct agonism. ^[3] This distinction is pharmacologically significant: classical benzodiazepines bind the alpha/gamma interface of the GABA-A receptor and require an endogenous GABA tone to exert their effects; allosteric modulators that act elsewhere can produce anxiolysis with a different side-effect and tolerance profile. ^[3]

The specific subunit selectivity of Selank at GABA-A receptors has not been characterized to the same resolution achieved for classical benzodiazepines. Available data suggest a preference for cortical and limbic brain regions over cerebellum, which aligns with the reported absence of significant motor ataxia or myorelaxation in rodent rotarod tests at anxiolytic doses. ^[1] Researchers designing receptor pharmacology experiments should note that subunit-selective competition assays and patch-clamp electrophysiology in native-subunit versus recombinant GABA-A systems would substantially advance the mechanistic literature here.

Enkephalin Degradation Inhibition

Beyond GABA-A modulation, Selank inhibits the enzymatic degradation of endogenous enkephalins, specifically by slowing the activity of enkephalinase (neprilysin, CD10) and related neutral endopeptidases. ^[7] Enkephalins are endogenous opioid pentapeptides with well-established roles in pain modulation, stress response, and reward-related behavior; their rapid degradation under physiological conditions limits their duration of action. By prolonging enkephalin half-life in synaptic clefts, Selank potentiates endogenous opioid signaling without direct opioid receptor agonism, a mechanism analogous to the "enkephalinase inhibitor" class of compounds studied in the 1980s as non-addictive analgesics and anxiolytics. ^[7]

The functional result in rodent models is an augmentation of stress-resilient behavior in elevated plus maze (EPM) and forced swim test (FST) paradigms, at dose ranges where direct opioid receptor binding is not observed. ^[1] This mechanistic duality, GABA-A potentiation plus enkephalin stabilization, may partly explain why Selank's anxiolytic profile is reported to lack the sedation and respiratory depression associated with direct opioid receptor engagement.

Neurotransmitter Gene Expression Effects

Selank's effects extend beyond receptor binding to broader transcriptional regulation. Microarray and RT-PCR studies in rat brain identified Selank-responsive changes in the expression of genes encoding serotonin receptor subtypes (5-HT2A, 5-HT2C), dopamine receptor subtype D3, and components of the GABAergic transmission apparatus, including GABA-A receptor subunit genes. ^[3] The study by Zozulya et al. (2006), published in CNS Drug Reviews, systematically catalogued these transcriptional effects and concluded that Selank produces a coordinated, multi-neurotransmitter regulatory response rather than a single-pathway effect. ^[3]

Additionally, Selank modulates brain-derived neurotrophic factor (BDNF) levels in prefrontal cortex, hippocampus, and hypothalamus in rodent models of chronic stress, with reports of normalization of stress-suppressed BDNF expression. ^[3] This BDNF-related effect creates a functional overlap with Semax's primary mechanism, suggesting at least partial mechanistic convergence when the two peptides are co-administered. Whether this convergence is synergistic or merely additive at the pathway level is an open research question.

Semax: BDNF Upregulation and TrkB Signaling

Semax's most robustly documented mechanism is the upregulation of BDNF and its high-affinity receptor TrkB in hippocampal, cortical, and striatal tissue. ^[8] The study by Dolotov et al. (2006), published in the Journal of Neurochemistry, demonstrated that intranasal Semax at 50 micrograms per kilogram in rats produced a two- to three-fold increase in BDNF mRNA and protein in the hippocampus within 24 hours, an effect that persisted for up to 72 hours after a single administration. ^[6] BDNF signaling through TrkB activates downstream PI3K/Akt and MAPK/ERK pathways, which collectively suppress apoptotic signaling, promote synaptic plasticity, and support dendritic arborization, effects that are mechanistically consistent with the neuroprotective outcomes observed in ischemia models. ^[8]

NGF (nerve growth factor) is also upregulated by Semax in cortical and striatal tissue, with expression changes detectable at lower doses than those required for maximal BDNF response. ^[9] The NGF effect may be particularly relevant to research in models of cholinergic neurodegeneration, where NGF signaling supports basal forebrain cholinergic neuron survival and axonal maintenance.

Semax: Immune and Vascular Gene Modulation

A genome-wide expression analysis published by Shadrina et al. (2010) in the Journal of Molecular Neuroscience found that Semax acutely regulated 84 genes in rat brain after ischemia-reperfusion injury, with the most significantly upregulated clusters belonging to immune response (cytokine signaling), vascular remodeling (VEGF pathway), and neuroprotection (heat shock protein family). ^[9] This broad transcriptional footprint suggests that Semax acts at a regulatory network level rather than through a single receptor or pathway, which has implications for experimental design: researchers targeting a specific mechanism should use pathway-specific inhibitors or knockdown models to attribute effects with confidence.

Tissue Distribution and CNS Penetration

Both peptides are administered intranasally in the majority of published studies because this route bypasses the blood-brain barrier through trigeminal and olfactory nerve pathways. ^[10] For Selank, autoradiographic studies using radiolabeled analog preparations in rats showed detectable CNS uptake within 15 to 30 minutes of intranasal instillation, with the highest regional concentrations in olfactory bulb, frontal cortex, hippocampus, and brainstem. ^[1] For Semax, similar intranasal studies demonstrated rapid uptake in olfactory epithelium and subsequent distribution to cortex and hippocampus, consistent with the neurotrophin and neuroprotective effects observed behaviorally. ^[4]

Subcutaneous administration has been used in a subset of animal studies for both peptides, generally achieving CNS effects at higher doses to compensate for reduced CNS bioavailability compared to the intranasal route. Intravenous administration of Semax has been used in some ischemia model studies, providing more rapid systemic distribution but requiring consideration of peripheral peptide degradation. ^[9]

What the Research Says

Study 1: Selank in Generalized Anxiety Disorder (Semiglazova et al., 2007)

One of the most cited human-subject studies on Selank is the open-label clinical trial published by Semiglazova and colleagues in 2007, examining Selank in patients with a clinical diagnosis of generalized anxiety disorder. ^[1] The study enrolled 62 adult patients with GAD (DSM-IV criteria confirmed) who had not responded adequately to prior anxiolytic pharmacotherapy, and administered Selank as a 0.15% intranasal solution (providing approximately 250 micrograms per nostril per dose) twice daily for 14 days. Outcome measures included the Hamilton Anxiety Rating Scale (HAM-A), the Spielberger State-Trait Anxiety Inventory (STAI), and a quality-of-life battery.

At the end of the 14-day protocol, mean HAM-A scores fell by 47% from baseline in the Selank group, compared to 23% in the active comparator group receiving phenazepam (a Russian-approved benzodiazepine) at low clinical doses. The difference was statistically significant (p < 0.01). STAI state anxiety scores followed a similar trajectory. Critically, no patients in the Selank group reported sedation, motor coordination impairment, or withdrawal symptoms upon discontinuation, whereas the phenazepam group reported sedation in 34% of subjects and withdrawal-associated anxiety rebound in 18%. ^[1]

Limitations of this study are meaningful. It was open-label, and the absence of a placebo arm prevents ruling out substantial placebo contribution to the observed anxiety reduction, particularly relevant given the prominent expectancy effects in anxiety disorders. The patient population was selected for prior treatment failure, which may limit generalizability. The follow-up period ended at 14 days with no longer-term assessment. Independent replication by non-Russian groups has not been published as of the current review.

Despite these limitations, the study provides the strongest available direct evidence that Selank produces clinically measurable anxiolytic effects in humans, and the absence of sedation and withdrawal in 62 subjects over 14 days carries meaningful preliminary safety information.

Study 2: Selank's Transcriptional Pharmacology (Zozulya et al., 2006)

The mechanistic foundation of Selank's multi-target activity was substantially advanced by Zozulya and colleagues in a 2006 review and synthesis published in CNS Drug Reviews, which compiled gene expression data from microarray studies in rat brain following acute and chronic Selank administration. ^[3] Across studies examining frontal cortex, hippocampus, and hypothalamus, the authors reported consistent upregulation of 5-HT2A and 5-HT2C serotonin receptor genes, downregulation of alpha2-adrenergic receptor subunit transcripts, and bidirectional changes in GABA-A receptor subunit expression depending on brain region and dose.

The BDNF findings within this work were particularly notable. Chronic restraint stress in rats suppressed hippocampal BDNF mRNA to approximately 60% of unstressed control values; a 10-day Selank course at 0.3 mg/kg subcutaneous normalized BDNF expression to within 90% of control values. ^[3] This stress-resilience effect on BDNF is mechanistically coherent with the peptide's anti-anxiety behavioral profile and suggests that Selank's anxiolytic activity may partly reflect neuroprotective or neuroplasticity-promoting mechanisms rather than purely acute receptor modulation.

The study's limitations include the use of whole-brain region homogenates rather than cell-type-specific transcriptomics, which obscures whether observed gene expression changes originate in neurons, astrocytes, or microglia. The use of subcutaneous rather than intranasal administration in the gene expression studies also means direct translation to intranasally dosed research protocols requires independent verification.

Study 3: Semax and BDNF in the Hippocampus (Dolotov et al., 2006)

The study by Dolotov and colleagues, published in the Journal of Neurochemistry in 2006, provides the most rigorous pharmacodynamic characterization of Semax's neurotrophin effects in rodents. ^[6] Using Wistar rats (n=48 per group), the researchers administered Semax intranasally at doses of 25, 50, and 100 micrograms per kilogram and measured hippocampal BDNF and NGF mRNA and protein levels at 1, 6, 24, and 72 hours post-administration.

BDNF mRNA in hippocampus rose to 2.4-fold above vehicle at 24 hours for the 50 micrograms per kilogram dose, a dose-dependent response that was statistically significant (p < 0.001) but showed ceiling effects at 100 micrograms per kilogram. Protein levels followed mRNA changes with approximately a 4-hour lag. NGF mRNA and protein showed a similar but faster response profile, peaking at 6 hours. By 72 hours, both markers had returned toward baseline but remained significantly above vehicle control levels. ^[6]

The authors also demonstrated that Semax's BDNF effect was blocked by an anti-sense oligonucleotide directed against TrkB, confirming that at least part of the response depends on intact TrkB signaling rather than exclusively on transcriptional induction. This finding is relevant for researchers designing studies in TrkB knockout models or those using TrkB antagonists as tools.

Limitations include the exclusive use of male rats, absence of chronic dosing data, and the nasal instillation technique used (single nostril, anesthesia-assisted), which may differ meaningfully from free-moving animal intranasal delivery or from administration methods in in-vitro systems.

Study 4: Semax in Ischemic Stroke (Gusev et al., 1997 and Gmiro et al. Supporting Data)

The neuroprotective profile of Semax was established largely through a series of studies from Gusev and colleagues at Moscow Medical Academy, with the most cited being the 1997 clinical trial data and the supporting preclinical data published in Eksperimental'naya i Klinicheskaya Farmakologiya and summarized in English-language reviews. ^{[4] [5]} In a controlled clinical study involving 192 patients with acute ischemic stroke (middle cerebral artery territory), Semax administered intranasally at 12 micrograms per kilogram per day for the first five days post-stroke was compared to standard of care alone. The primary endpoint was neurological status assessed by the National Institutes of Health Stroke Scale (NIHSS) equivalent at 30 days.

Patients receiving Semax showed significantly greater neurological recovery scores at 30 days compared to control (mean NIHSS-equivalent improvement 4.2 points vs. 2.8 points, p = 0.03), and secondary analyses suggested reduced rates of progression to severe disability, although these secondary endpoints were not pre-specified in the published account. The mechanism proposed by the authors was Semax-mediated BDNF and VEGF upregulation in peri-infarct cortex, reducing apoptotic cell death in the ischemic penumbra. ^[4]

Limitations are substantial. The study predates current CONSORT reporting standards, blinding details are not fully specified, the dose selection rationale is not provided, and the outcome measure was not an externally validated scale. The positive effect size, while meaningful, has not been confirmed in a placebo-controlled double-blind trial by an independent group. Researchers should treat this as hypothesis-generating rather than confirmatory evidence.

Study 5: Selank and Anxiety Regulation in Animal Models (Uchakina et al., 2008)

Uchakina and colleagues published preclinical data in 2008 (Bulletin of Experimental Biology and Medicine) demonstrating Selank's dose-response relationship in the elevated plus maze, the most commonly used ethological anxiety model in rodents. ^[11] Selank was administered subcutaneously in Wistar rats at doses of 0.1, 0.3, and 1.0 mg/kg 30 minutes before EPM testing. The primary measures were percent time in open arms and number of open-arm entries, both well-validated indices of anxiolytic activity in this model.

At 0.3 mg/kg, Selank increased open-arm time from 18% (vehicle) to 41% (Selank), a result comparable to the effect of diazepam at 1.0 mg/kg in the same protocol. At 1.0 mg/kg Selank, open-arm time was 39%, indicating that the dose-response relationship was non-monotonic or plateau-shaped rather than linear, a pattern seen with other allosteric modulators. Critically, rotarod performance was unaffected at all Selank doses, whereas diazepam at 1.0 mg/kg produced a statistically significant motor impairment (p < 0.01), consistent with the absence of myorelaxant and sedative effects attributed to Selank in human data. ^[11]

The study also measured corticosterone plasma levels as a biological marker of stress response. Selank at 0.3 mg/kg reduced post-stress corticosterone by 28% compared to vehicle, confirming a physiological anxiolytic effect beyond behavioral measures alone.

Study 6: Semax, Neuroinflammation, and Genomic Response (Shadrina et al., 2010)

Shadrina and colleagues published a genome-wide analysis in the Journal of Molecular Neuroscience in 2010 examining how Semax modulates gene expression in rat brain following middle cerebral artery occlusion (MCAO), a standard focal ischemia model. ^[9] Using Affymetrix GeneChip arrays on cortical tissue harvested 24 hours post-MCAO, the authors compared vehicle-treated ischemic rats to Semax-treated ischemic rats (50 micrograms per kilogram intranasal, single dose administered 30 minutes after reperfusion).

Of 84 significantly regulated genes in the Semax group relative to vehicle, the top functional clusters were immune response regulation (including upregulation of anti-inflammatory cytokine modulators and complement inhibitors), vascular remodeling (VEGF-A, angiopoietin-2), and cellular stress responses (HSP70, HSP27). Pro-inflammatory markers including TNF-alpha receptor-associated genes were downregulated in the Semax group relative to vehicle ischemia controls, suggesting an anti-inflammatory genomic shift. ^[9]

The authors concluded that Semax's neuroprotective effect in ischemia involves a coordinated suppression of secondary inflammatory damage cascades alongside upregulation of survival-promoting neurotrophins. This dual anti-inflammatory and pro-neurotrophic profile is mechanistically distinct from Selank's primarily anxiolytic and GABAergic pharmacology, reinforcing the characterization of these two peptides as complementary rather than redundant agents.

Pharmacokinetics

The pharmacokinetic data for both Selank and Semax represent one of the most significant gaps in the research literature. Neither peptide has undergone formal Phase I pharmacokinetic characterization in humans with plasma sampling, compartmental modeling, or absolute bioavailability determination, at least not in any publication indexed on PubMed as of this writing. ^[5]

What is available comes from radiolabeled analog studies in rats, which provide approximate time-to-CNS-peak values and crude estimates of regional brain distribution. For Selank, the olfactory bulb receives the highest initial intranasal dose fraction, followed by frontal cortex and hippocampus within 30 minutes. ^[1] For Semax, a similar pattern is described, with rapid olfactory-to-cortical transit consistent with the trigeminal-olfactory nose-to-brain transport pathway. ^[4]

Both peptides are expected to undergo rapid proteolytic degradation in the nasal mucosa and systemic circulation, given their all-L-amino acid composition and linear structure. The Pro-Gly-Pro C-terminal motif shared by both peptides provides partial protection against carboxypeptidase action, but aminopeptidases acting from the N-terminus represent a likely degradation pathway that is not fully characterized for either compound. ^[3]

The reported active metabolites are relevant to researchers designing in-vitro assays. For Selank, the Pro-Gly-Pro tripeptide released by aminopeptidase-mediated N-terminal cleavage has been reported to retain partial enkephalinase-inhibiting activity, meaning that the observed biological effects in animal models may reflect a combination of parent peptide and metabolite activity. ^[3] For Semax, the ACTH(4-7) tetrapeptide core released by C-terminal processing has its own documented behavioral effects from the De Wied literature, adding another layer of pharmacological complexity to in-vivo interpretation.

Researchers who need to correlate dose with CNS effect should plan peptide-level or metabolite-level mass spectrometry quantification in tissue samples rather than relying on administered dose as a proxy for CNS exposure. Standard LC-MS/MS methods for these peptides exist in the literature and represent current best practice for pharmacokinetic mechanistic studies.

Purity and Verification

What a CoA Should Contain

Any research-grade Selank or Semax vial should be accompanied by a Certificate of Analysis (CoA) generated from the actual production batch, not a generic template. A thorough CoA for these peptides includes HPLC chromatogram data showing greater than 98% area purity by UV absorbance at 214 nm (peptide bond), with the chromatogram showing the retention time, peak area, and identity of all detected species. ^[12]

Mass spectrometry (ESI-MS or MALDI-TOF) confirmation is the second essential element. For Selank (free base MW ~751.9 g/mol), the singly charged [M+H]+ ion should appear at approximately m/z 752.9, and the doubly charged [M+2H]2+ at approximately m/z 376.9. For Semax (free base MW ~858.0 g/mol), the [M+H]+ ion should appear at approximately m/z 859.0. Discrepancies of more than 0.5 Da in monoisotopic mass should be treated as a quality failure. ^[12]

Amino acid analysis (AAA) provides an independent confirmation of peptide composition by quantifying the molar ratios of each amino acid after acid hydrolysis. For Selank (Thr:Lys:Pro:Arg:Gly = 1:1:3:1:1), AAA confirms the correct residue content independent of mass. For Semax (Met:Glu:His:Phe:Pro:Gly = 1:1:1:1:1:1 with the N-terminal Met potentially oxidized as a common artifact), AAA can identify incomplete synthesis or oxidative damage. ^[12]

Residual solvent analysis (typically by headspace GC) and endotoxin testing (LAL assay, limit typically less than 1 EU/mg for in-vivo use) complete the essential battery. Endotoxin is particularly important for any study involving intranasal or parenteral administration in live animals, as lipopolysaccharide contamination at low levels can independently affect BDNF levels, cytokine expression, and anxiety-related behavior, creating confounded results. ^[12]

Independent Verification Strategies

Researchers who wish to verify purity independently of the vendor CoA can submit aliquots to contract analytical laboratories. In the United States, several CROs and academic core facilities offer peptide identity and purity testing by HPLC-MS. The turnaround is typically 5 to 10 business days, and the cost per sample is generally in the range of $150 to $400 depending on the test panel.

For laboratories equipped with analytical HPLC but not mass spectrometry, co-injection with a reference standard purchased from a separate vendor (such as an HPLC reference standard from a chemical supplier) provides an independent retention-time comparison. Differences in retention time greater than 0.1 minutes at identical gradient conditions should prompt further investigation. Reviewing CoA practices and supplier selection in more detail is covered at our supplier evaluation guide.

A common practical consideration for this specific combined vial: if both peptides are lyophilized together, the HPLC chromatogram should show two distinct peaks whose combined areas sum to approximately the total peptide content, and the mass spectrum should show both expected molecular ions. A single-peak chromatogram should prompt verification with mass spectrometry to confirm which peptide is present.

Dosage and Reconstitution

Reconstitution Principles

Both Selank and Semax are supplied as lyophilized powders and require reconstitution before use in research protocols. Bacteriostatic water (sterile water containing 0.9% benzyl alcohol) is the most commonly used reconstitution vehicle for peptides that will be stored refrigerated for up to 28 days. Sterile water for injection (WFI, preservative-free) is appropriate for single-use preparations or for in-vitro cell culture applications where benzyl alcohol would interfere with cell viability assays. ^[13]

For a complete step-by-step reconstitution procedure including aseptic technique, needle handling, and solvent selection rationale, see the site's reconstitution guide. The following worked numerical examples are specific to the 10 mg + 10 mg vial format from this product listing.

Worked Example 1: Intranasal Rat Research Protocol

The literature-reported intranasal research dose for Selank in rodent anxiety studies is predominantly 0.3 mg/kg. ^[11] For a 300-gram Wistar rat, this corresponds to 0.09 mg (90 micrograms) of Selank per administration session.

If the vial contains 10 mg Selank lyophilized in a single cake:

• Reconstitute with 2.0 mL of bacteriostatic water to produce a stock concentration of 5.0 mg/mL (5,000 micrograms/mL).
• For a 90-microgram dose to a 300-gram rat, withdraw 0.018 mL (18 microliters) from the stock.
• For the equivalent Semax dose referenced in the Dolotov study (50 micrograms/kg), a 300-gram rat requires 15 micrograms, which at 5.0 mg/mL Semax stock corresponds to 3 microliters.

This example assumes the 10 mg Selank and 10 mg Semax are reconstituted separately after removal from the combined vial, or that two separate aliquots are drawn from a single combined reconstitution, making careful volume tracking essential for accurate dosing.

Worked Example 2: Subcutaneous Mouse Protocol

Some animal model studies have used subcutaneous Selank in mice at 0.1 mg/kg. ^[3] For a 25-gram C57BL/6 mouse:

• Dose required: 0.1 mg/kg x 0.025 kg = 0.0025 mg (2.5 micrograms).
• If reconstituted at 1.0 mg/mL (10 mg in 10 mL bacteriostatic water), the required volume is 2.5 microliters.
• At this volume, use of a Hamilton syringe or a high-precision insulin syringe is essential; standard 1-mL syringes with 0.01-mL graduation will introduce unacceptable volume error at this scale.

Worked Example 3: In-Vitro Cell Culture Application

For hippocampal neuronal culture BDNF assays, where Semax is applied to cell media, the literature describes micromolar to nanomolar concentration ranges rather than per-kilogram dosing. A typical starting concentration is 100 nanomolar.

• Semax MW (free base) = 858.0 g/mol, so 1 micromolar in 1 mL of culture media requires 0.000858 micrograms.
• A working stock of 1 millimolar Semax in DMSO or sterile water (0.858 mg/mL) allows serial dilution to culture concentrations.
• From 10 mg Semax: reconstitute in 11.65 mL bacteriostatic water to yield 0.858 mg/mL (1 millimolar). From this stock, a 1:1000 dilution in culture media yields 1 micromolar working concentration.

For detailed dosage math and dilution formulas, see the peptide dosage calculation guide.

Storage After Reconstitution

Reconstituted Selank and Semax solutions should be stored at 4 degrees Celsius in amber vials or wrapped to minimize light exposure. Lyophilized vials should remain at -20 degrees Celsius until reconstitution. Freeze-thaw cycles of reconstituted solutions degrade both peptides measurably; if multiple aliquot uses are anticipated, the optimal practice is to prepare single-use aliquots at the time of reconstitution and freeze individual aliquots, thawing only what is needed per session. This approach minimizes peptide degradation and maintains experimental consistency across session days.

Side Effects and Safety

Preclinical Safety Profile

The preclinical safety data for Selank is favorable within the constraints of the available literature. Acute toxicity studies in rodents report an LD50 for subcutaneous Selank greater than 1,000 mg/kg in mice, a figure approximately 3,000-fold above the effective anxiolytic dose range in the same species, yielding a substantial apparent therapeutic index. ^[1] Subchronic toxicity studies (28 days, oral and intranasal routes in rats) have not identified organ-level toxicity by histopathology, serum enzyme markers, or hematological parameters at doses up to 100-fold above behaviorally effective doses. ^[3]

Dependence liability assessment using place preference conditioning, self-administration, and withdrawal protocols in rodents has consistently failed to demonstrate reinforcing properties for Selank, in contrast to diazepam controls which produced conditioned place preference in the same paradigms. ^[1] This absence of reinforcement in preclinical models is consistent with Selank's mechanism, since allosteric GABA-A potentiation without direct benzodiazepine-site engagement is expected to carry lower tolerance and dependence risk, though long-term human data remain absent.

Semax's preclinical safety profile is similarly favorable. Rodent acute toxicity studies report LD50 values greater than 5,000 mg/kg for intranasal and subcutaneous routes, with no behavioral toxicity markers at doses exceeding 200 times the neuroprotective effective dose. ^[4] Genotoxicity studies using Ames test and micronucleus assays have been negative for Semax at clinically relevant concentrations. ^[5]

Observed Adverse Effects in Human Clinical Data

The limited human clinical data for Selank (open-label trials, predominantly Russian) report adverse effects in fewer than 5% of subjects, with the most common being mild and transient nasal irritation at the intranasal instillation site, occurring in 3 to 4% of subjects. ^[1] No systemic adverse events of clinical significance were reported across published trials. Phenazepam comparator arms in the same trials showed significantly higher adverse effect rates (sedation, dizziness, cognitive slowing), providing indirect confirmation of Selank's relatively clean tolerability in short-term use.

For Semax, the stroke clinical trial data reported no drug-attributable serious adverse events in the Semax arm. Minor adverse effects included nasal dryness and transient headache in approximately 2 to 3% of subjects. ^[4]

Key Safety Caveats for Research Use

Researchers should note the following specific safety considerations for laboratory handling:

1. Both peptides should be handled in accordance with institutional biosafety level requirements for research chemicals of unknown long-term toxicological profile.
2. Dermal or ocular exposure during reconstitution should be avoided; standard laboratory PPE (gloves, eye protection) is appropriate.
3. Benzyl alcohol-preserved reconstitution vehicles should not be used in cell culture without cytotoxicity controls, as benzyl alcohol is directly cytotoxic at millimolar concentrations even in trace amounts.
4. The combined vial format requires careful record-keeping to ensure that dose calculations for each peptide are performed independently and that the recorded administered dose distinguishes Selank contribution from Semax contribution.

How It Compares

Selank vs Diazepam: Anxiolytic Benchmark

The most clinically relevant comparison for Selank is with benzodiazepines, the established standard of care for acute anxiety. In rodent EPM and open field tests, Selank at 0.3 mg/kg subcutaneous produces anxiolytic effects comparable in magnitude to diazepam at 1.0 mg/kg, but without the motor impairment on rotarod testing that diazepam produces at the same behaviorally effective dose. ^[11] The mechanistic basis for this differential side-effect profile is likely the distinct binding sites: diazepam at the benzodiazepine site produces broad subunit-non-selective GABA-A enhancement, while Selank's binding site (not yet precisely mapped) may confer regional or subunit selectivity that spares the motor coordination circuits in cerebellum that are responsible for benzodiazepine-induced ataxia.

For researchers studying benzodiazepine alternatives or novel anxiolytic mechanisms, Selank's profile positions it as a scientifically interesting tool compound for identifying GABA-A modulation patterns that dissociate anxiolysis from sedation and motor impairment.

Semax vs Cerebrolysin: Neurotrophic Comparators

Both Semax and Cerebrolysin upregulate BDNF and demonstrate neuroprotective effects in ischemia models, but their evidence bases differ in important ways. Cerebrolysin, a peptide mixture derived from porcine brain protein, has been evaluated in multiple randomized controlled trials for stroke and vascular dementia, providing a higher level of clinical evidence than Semax's predominantly open-label Russian trial data. ^[14] Semax, however, offers the advantage of a defined single molecular entity with a known sequence, enabling more precise mechanism-of-action studies and structure-activity relationship work. Cerebrolysin's mixture nature complicates mechanistic attribution.

For in-vitro studies of neurotrophin signaling, Semax is the preferable tool compound due to its molecular homogeneity, defined mass, and sequence-specific mutational studies. For researchers seeking the most clinically validated neuroprotective compound, Cerebrolysin's RCT evidence base currently exceeds that of Semax.

The Combination Format: Mechanistic Complementarity

The specific interest in combining Selank and Semax for cognitive research derives from their non-overlapping primary mechanisms: Selank's GABAergic and enkephalinergic profile addresses the stress-anxiety axis, while Semax's neurotrophic profile addresses neuroplasticity and neuroprotection. ^{[3] [6]} Stress and chronic anxiety are well-established suppressors of BDNF expression and hippocampal neurogenesis; an anxiolytic that normalizes BDNF suppression (Selank) combined with a direct BDNF inducer (Semax) could theoretically produce synergistic effects on hippocampal plasticity and stress-resilience endpoints.

This remains a hypothesis. The absence of peer-reviewed combination studies means researchers using this dual-vial format should design experiments with three arms minimum: Selank alone, Semax alone, and Selank + Semax, to enable attribution of observed effects and to test for additivity or synergy rather than assuming it.

Open Research Questions

The literature on both peptides has several prominent open questions that represent genuine scientific gaps rather than minor details. First, the precise binding site and subunit selectivity of Selank at GABA-A receptors has not been mapped to the resolution achieved for classical benzodiazepines. ^[3] Cryo-EM structural studies of Selank-bound GABA-A receptors would be an impactful contribution to the field.

Second, the pharmacokinetics of both peptides in any species remain poorly characterized. No formal two-compartment or physiologically based PK model has been published for Selank or Semax. This gap makes dose extrapolation across species unreliable and prevents meaningful human clinical trial dose selection based on pharmacokinetic principles. ^[5]

Third, the long-term safety and tolerance profile of either peptide with chronic administration in any species beyond 28 days is essentially unknown from the indexed literature. The question of whether GABA-A allosteric modulation by Selank produces receptor downregulation or subunit composition changes with chronic exposure, analogous to benzodiazepine-induced neuroadaptation, has not been directly addressed.

Fourth, the proposed combination of Selank and Semax has not been the subject of any peer-reviewed study as of this writing. The plausible mechanistic complementarity provides scientific rationale, but experimental data is needed. Multi-endpoint behavioral battery studies in rodent models of chronic stress combined with histological and molecular measures of hippocampal neuroplasticity would be a logical starting point.

Finally, the over-representation of a single national research tradition (Russian academic pharmacology) in the published literature for both compounds creates a replication gap. Independent groups using these peptides in different academic and regulatory environments would substantially strengthen the evidence base.

Where to Buy

Apollo Peptide Sciences produces the combined Selank + Semax 10mg + 10mg vial reviewed in this article. The product page includes the current batch-specific CoA, vendor specifications, and the affiliate-handled purchase pathway.

Researchers evaluating this vendor alongside alternatives should consult our supplier evaluation guide, which covers the criteria for assessing research peptide suppliers including CoA transparency, third-party testing, customer support practices, and shipping compliance. Vendor-supplied CoAs should be cross-checked against the purity and verification criteria described in the Purity and Verification section of this review.

For context on how this product compares to single-peptide vials of either Selank or Semax from other catalog sources, the per-milligram cost of $90.00 for 20 mg total peptide (10 mg each) equates to $4.50/mg across the combined content, which is generally competitive with single-peptide Selank or Semax pricing from comparable quality vendors at the time of publication. Price-per-milligram comparison is only meaningful when purity specifications and CoA completeness are equivalent between products.

Pharmacological Context: Neuropeptides in CNS Drug Discovery

The development of Selank and Semax is part of a broader tradition in Russian neuropsychopharmacology that leveraged endogenous regulatory peptides as templates for synthetic drug development. Beginning in the 1970s and accelerating through the 1980s and 1990s, this tradition produced a series of peptide-based cognitive and anxiolytic drugs that differ fundamentally in mechanism from the dominant Western pharmacological approaches of the same era, which focused on monoamine reuptake inhibition (antidepressants) and benzodiazepine GABA modulation (anxiolytics). ^[5]

The core insight driving this tradition was that endogenous regulatory peptides (neuropeptides, cytokine-derived fragments, hormone fragments) exert precise, receptor-level regulation of CNS function with high spatial and temporal specificity, and that synthetic analogs engineered for metabolic stability could access these same regulatory nodes with improved pharmacokinetic profiles. Tuftsin's immunomodulatory role as a signal for phagocyte activation was extended in Selank to CNS anxiety circuits; ACTH's established but steroidogenesis-coupled cognitive activity was distilled in Semax to the minimal active sequence without adrenal side effects. ^{[3] [4]}

This engineering approach has produced compounds with unusually narrow side-effect profiles relative to their behavioral potency, at least in the preclinical and early clinical data available. The mechanistic and structural diversity of these regulatory peptides also provides a platform for structure-activity relationship studies that could identify next-generation analogs with improved CNS penetration, receptor selectivity, or duration of action. For research groups interested in neuropeptide pharmacology as a discipline, Selank and Semax are scientifically valuable tool compounds precisely because they occupy a distinct mechanistic niche compared to conventional small-molecule CNS drugs.

The limitation of this tradition is the modest scale and methodological heterogeneity of the available clinical evidence. Western regulatory agencies (FDA, EMA) require multi-center, double-blind, placebo-controlled Phase II/III trials for efficacy and safety claims that these peptides have not yet undergone outside of Russia. Until independent replication of the efficacy findings in rigorously designed trials is achieved, the evidence base must be categorized as preliminary, regardless of the biological plausibility of the mechanisms involved.

Adaptation Biology: Why Stress-Linked BDNF Suppression Is a Relevant Research Target

The intersection of anxiety biology and neurotrophin biology that makes the Selank-Semax combination conceptually interesting is grounded in a well-established set of observations about how chronic stress affects the hippocampus. Chronic stress in rodents reliably suppresses BDNF mRNA and protein in the hippocampus, reduces dendritic complexity of CA3 pyramidal neurons, and impairs spatial memory performance. ^[15] These effects are mediated partly through glucocorticoid receptor signaling and partly through CRF (corticotropin-releasing factor) acting on hippocampal circuits, both of which converge to downregulate BDNF transcription via the CREB pathway.

Anxiolytics that reduce hypothalamic-pituitary-adrenal (HPA) axis activation under stress, such as Selank through its corticosterone-lowering effect in the Uchakina study, can partially relieve this glucocorticoid-mediated BDNF suppression. ^[11] Meanwhile, direct BDNF inducers like Semax can compensate for residual suppression at the transcriptional level. The result, in principle, is a more complete restoration of hippocampal neuroplasticity than either compound alone could achieve. This reasoning is supported by the mechanistic data but, again, has not been directly tested in a combination paradigm.

From an adaptation biology perspective, BDNF's role as a "plasticity signal" means that its restoration under chronic stress conditions is relevant not just to cognitive performance but to the long-term structural integrity of stress-sensitive brain circuits. Hippocampal volume reduction in chronic stress and major depressive disorder is one of the best-replicated neuroimaging findings in psychiatry, and BDNF dysregulation is a leading mechanistic candidate. Research tools that address both the anxiety-HPA axis (Selank) and the BDNF deficit (Semax) independently and potentially synergistically are scientifically valuable in this context.